Mouton, Y., Chidiac, C., Humbert, G., Leroy, J., Veyssier, P., Modai, J., ...
Multi-resistant strains of Gram-negative bacteria are rapidly emerging as a frequent cause of serious bacterial infection in the hospital environment. Effective treatment must include an antibiotic...
Gouin, F., Papazian, L., Martin, C., Albanese, J., Durbec, O., Domart, Y., ...
Patients in intensive care units (ICUs) are at increased risk of developing nosocomial infections. This is of special concern in the immunocompromised patient, particularly with regard to...
Pharmacokinetics of cefodizime in elderly patients with moderate or severe renal impairment (1990)
Veyssier, P., Devillers, A., Domart, Y., Fourtillan, J. B., Bryskier, A., Procyk, T.
In young adults, the elimination half-life of cefodizime is 3.5–4 h. A pharmacokinetic study was performed in eight patients, aged 63 to 85 years, divided into two groups with the following...
Reedijk, M, Boucher, C A, Van Bommel, T, Ho, D D, Tzeng, T B, Sereni, D, ...
A77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, was administered to asymptomatic HIV-1-infected patients in a phase I trial. The drug was given by continuous...
Reedijk, M, Boucher, C A, Van Bommel, T, Ho, D D, Tzeng, T B, Sereni, D, ...
A77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, was administered to asymptomatic HIV-1-infected patients in a phase I trial. The drug was given by continuous...